Congress Mulls Passage of CREATES Act


The CREATES Act , currently pending in Congress states as its aim to promote drug price competition by removing an impediment to the development and approval of lower cost generics or biosimilars. Currently some branded companies are using safety requirements, including restricted distribution programs and REMS requirements, as a pretext for refusing to sell samples of their brand-name products to companies interested in developing generic and biosimilar products.



from Biotech News